Anebulo Zero Revenue, Eyes Cannabis Toxicity Treatment Amid Go-Private Plan

TL;DR

**ANEB is a high-risk, pre-revenue biotech betting it all on one drug for cannabis toxicity, but a potential delisting makes it a speculative gamble for retail investors.**

AI Summary

Anebulo Pharmaceuticals, Inc. (ANEB) reported no revenue since its inception and anticipates future losses, indicating a pre-commercial stage. The company's primary focus is the development of selonabant (formerly ANEB-001), a lead product candidate aimed at rapidly reversing cannabis-induced toxicity, including acute cannabis-induced toxicity in children and acute cannabinoid intoxication (ACI) in adults. This addresses a significant unmet medical need, as there are no currently approved treatments for these conditions. The filing highlights the growing public health issue of cannabis-induced toxicity, with an estimated 1.1 million cannabis-related emergency department visits in the U.S. in 2014, underscoring the potential market for selonabant. Anebulo faces substantial risks, including the need for additional capital, the lengthy and expensive clinical trial process, and the uncertainty of regulatory approvals. The company's market value of non-affiliate common stock was $15,057,677 as of December 31, 2024, with 41,084,731 shares outstanding as of September 25, 2025. Anebulo is also considering a reverse stock split and a plan to go private, which could significantly impact its public market presence.

Why It Matters

Anebulo's pursuit of selonabant could be a game-changer for emergency medicine, offering the first specific treatment for cannabis-induced toxicity, a condition driving 1.1 million U.S. emergency department visits in 2014. For investors, the company's pre-revenue status and reliance on future capital raises, coupled with a proposed reverse stock split and delisting, signal high risk and potential illiquidity. Employees face uncertainty given the company's early stage and the critical need for successful clinical trials and regulatory approvals. Customers, particularly those in healthcare, could benefit immensely from a targeted treatment, potentially reducing hospital stays and improving patient outcomes in a market currently lacking specific solutions.

Risk Assessment

Risk Level: high — Anebulo Pharmaceuticals has not generated any revenue since its inception and expects to incur future losses, as stated in the 'Risks Related to our Business, Financial Condition and Capital Requirements' section. The company's aggregate market value of non-affiliate common stock was only $15,057,677 as of December 31, 2024, and it intends to seek stockholder approval for a reverse stock split and a plan to go private, indicating significant financial and operational instability.

Analyst Insight

Investors should approach Anebulo with extreme caution, recognizing its pre-revenue status and the high-risk nature of drug development. Given the stated intention to go private and delist from Nasdaq, current shareholders should evaluate the implications of reduced liquidity and potential valuation changes, while new investors should avoid until the company's future public status and financing strategy are clear.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $15,057,677 — Aggregate market value of non-affiliate common stock (As of December 31, 2024, indicating a small market capitalization for a public company.)
• 41,084,731 — Shares of common stock outstanding (As of September 25, 2025, relevant for per-share calculations and potential dilution.)
• 1.1 million — Cannabis-related emergency department patient visits (Estimated in 2014, highlighting the significant market need for selonabant.)
• $0 — Revenue since inception (Indicates the company is in a pre-commercial stage and relies on financing.)

Key Players & Entities

• Anebulo Pharmaceuticals, Inc. (company) — Registrant
• ANEB (company) — Trading Symbol
• Nasdaq Stock Market LLC (regulator) — Exchange where common stock is registered
• selonabant (company) — Lead product candidate
• ANEB-001 (company) — Former name of lead product candidate
• Securities and Exchange Commission (regulator) — Regulatory body for filings
• Delaware (regulator) — State of incorporation
• THC (company) — Principal psychoactive constituent of cannabis
• United States (regulator) — Location of cannabis-induced toxicity issue

FAQ

Risk Factors

• Failure of Internal Controls [high — operational]: Failure to establish and maintain proper and effective internal control over financial reporting could harm operating results and the ability to operate the business.
• Increased Costs of Public Company Operations [medium — financial]: The company is incurring significantly increased costs as a result of operating as a public company, requiring substantial management time for compliance efforts.
• Changes in Accounting Principles [medium — financial]: Changes in accounting principles or guidance, or their interpretations, could result in unfavorable accounting charges or effects, potentially impacting previously filed financial statements and stock price.
• Emerging Growth Company Status and Accounting Standards [medium — financial]: Election to delay adoption of new accounting standards applicable to public companies may make financial statements less comparable to other public companies, potentially making securities less attractive to investors.
• Adverse Changes in Tax Laws [medium — regulatory]: Changes in tax laws or regulations applied adversely to the company or its customers may have a material adverse effect on business, cash flow, financial condition, or results of operations.
• Limited Use of Net Operating Loss Carryforwards [medium — financial]: The ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited.
• Analyst Coverage and Stock Performance [medium — market]: If analysts do not publish research or cease publishing reports, change recommendations adversely, or if actual results differ significantly from guidance, stock price and trading volume could decline.
• Impact of Health Epidemics or Pandemics [medium — operational]: Health epidemics or pandemics may adversely affect the company's business, financial condition, and results of operations.

Industry Context

Anebulo Pharmaceuticals operates in the biotechnology sector, specifically focusing on the development of novel therapeutics for acute conditions. The company's lead candidate, selonabant, targets cannabis-induced toxicity, a growing public health concern with no current approved treatments. The market potential is significant given the increasing prevalence of cannabis use and associated adverse events.

Regulatory Implications

Anebulo faces stringent regulatory hurdles typical of pharmaceutical development, including the need for extensive clinical trials and FDA approval for selonabant. The company's status as an emerging growth company may allow for delayed adoption of certain accounting standards, but it does not exempt it from rigorous drug development and approval processes.

What Investors Should Do

1. Monitor clinical trial progress and regulatory updates for selonabant.
2. Assess the company's cash burn rate and future financing needs.
3. Evaluate the potential impact of the proposed reverse stock split and going private plan.

Glossary

emerging growth company

A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year. (Anebulo qualifies for certain regulatory and reporting accommodations, including delayed adoption of new accounting standards.)

Year-Over-Year Comparison

As Anebulo Pharmaceuticals, Inc. is in a pre-commercial stage with no revenue reported since inception, year-over-year revenue comparisons are not applicable. The company's financial condition and risk profile are likely to remain heavily influenced by its ongoing development activities and capital raising efforts, with no significant changes in core operational metrics expected until clinical trial progress or regulatory milestones are achieved.

Key Financial Figures

• $0.001 — he Registrant's common stock, par value $0.001 per share, outstanding as of September

Filing Documents

• form10-k.htm (10-K) — 1855KB
• ex4-4.htm (EX-4.4) — 43KB
• ex19-1.htm (EX-19.1) — 38KB
• ex31-1.htm (EX-31.1) — 13KB
• ex31-2.htm (EX-31.2) — 13KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• ex97-1.htm (EX-97.1) — 5KB
• form10-k_001.jpg (GRAPHIC) — 119KB
• form10-k_002.jpg (GRAPHIC) — 166KB
• form10-k_003.jpg (GRAPHIC) — 79KB
• ex97-1_001.jpg (GRAPHIC) — 1217KB
• ex97-1_002.jpg (GRAPHIC) — 1638KB
• ex97-1_003.jpg (GRAPHIC) — 1661KB
• ex97-1_004.jpg (GRAPHIC) — 1546KB
• ex97-1_005.jpg (GRAPHIC) — 477KB
• 0001493152-25-016015.txt ( ) — 15642KB
• aneb-20250630.xsd (EX-101.SCH) — 31KB
• aneb-20250630_cal.xml (EX-101.CAL) — 42KB
• aneb-20250630_def.xml (EX-101.DEF) — 112KB
• aneb-20250630_lab.xml (EX-101.LAB) — 309KB
• aneb-20250630_pre.xml (EX-101.PRE) — 256KB
• form10-k_htm.xml (XML) — 606KB

Risk Factors

Item 1A. Risk Factors 26

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 60

Cybersecurity

Item 1C. Cybersecurity 60

Properties

Item 2. Properties 60

Legal Proceedings

Item 3. Legal Proceedings 61

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 61 PART II 61

Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 61

[Reserved]

Item 6. [Reserved] 61

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 62

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 71

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 71

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 71

Controls and Procedures

Item 9A. Controls and Procedures 71

Other Information

Item 9B. Other Information 72

Disclosure Regarding Foreign Jurisdictions that Prevents Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevents Inspections 72 PART III 72

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 72

Executive Compensation

Item 11. Executive Compensation 77

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 90

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 92

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 94 PART IV 95

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 95

Form 10-K Summary

Item 16. Form 10-K Summary 96 In this Annual Report on Form 10-K (this "Annual Report"), unless otherwise stated or as the context otherwise requires, references to "Anebulo Pharmaceuticals," "Anebulo," "the Company," "we," "us," "our" and similar references refer to Anebulo Pharmaceuticals, Inc. The Anebulo logo, and other trademarks or service marks of Anebulo Pharmaceuticals, Inc. appearing in this Annual Report are the property of Anebulo Pharmaceuticals, Inc. This Annual Report also contains registered marks, trademarks and trade names of other companies. All other trademarks, registered marks and trade names appearing in this Annual Report are the property of their respective holders. We do not intend our use or display of other companies' trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. 2 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), which are subject the "safe harbor" created by those sections. These forward-looking statements about us and our industry involve substantial risks and uncertainties and our actual results could differ materially from those anticipated in these forward-looking Annual Report. All statements other than statements of historical facts contained in this Annual Report, including statements regarding our future financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking "could," "will," "estimate," "continue,"

Risk Factors

Risk Factors If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed. We are incurring significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance efforts. Changes in accounting principles or guidance, or in their interpretations, could result in unfavorable accounting charges or effects, including changes to our previously filed financial statements, which could cause our stock price to decline. We are an emerging growth company and our election to delay adoption of new or revised accounting standards applicable to public companies may result in our financial statements not being comparable to those of some other public companies; as a result, our securities may be less attractive to investors. Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations. Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited. If securities or industry analysts do not publish or cease publishing research or reports about us, or if they change their recommendations adversely, or if our actual results differ significantly from our guidance, our stock price and trading volume could decline. Health epidemics or pandemics may adversely affect our business, financial condition and results of operations. Unstable market and economic conditions, geopolitical conditions, domestic and foreign trade policies, monetary policies and other factors beyond our control may have serious adverse consequences on our business, financial condition and stock price. Inflation may adversely affect us by increasing our costs. We are subject to stringent and evolving U.S. an

View Full Filing

View this 10-K filing on SEC EDGAR